Ceptaris wins FDA OK for lymphoma gel, clears path to $250M Actelion buyout

Ceptaris wins FDA OK for lymphoma gel, clears path to $250M Actelion buyout

Malvern, PA-based Ceptaris Therapeutics nailed a delayed FDA approval for Valchlor, a drug designed for the most common form of cutaneous T-cell lymphoma. And the OK clears the way for Switzerland's Actelion ($ATLN) to go ahead with a deal to buy the 

10
Like
Save

Comments

Write a comment

*